Shareholder Alert: Ademi LLP investigates whether Crinetics Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Crinetics (Nasdaq: CRNX ) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Vertex. Crinetics shareholders will receive $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, or $8.8 billion net of estimated cash acquired. Crinetics insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Crinetics by imposing a significant penalty if Crinetics accepts a competing bid. We are investigating the conduct of the Crinetics board of directors, and whether they are fulfilling their fiduciary duties to all shareholders. We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights.